S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Forecast, Price & News

$1.45
-0.02 (-1.36%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.44
▼
$1.46
50-Day Range
$1.36
▼
$1.77
52-Week Range
$0.72
▼
$3.85
Volume
111,219 shs
Average Volume
129,254 shs
Market Capitalization
$117.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.88
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
167.8% Upside
$3.88 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.38) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

838th out of 961 stocks

Pharmaceutical Preparations Industry

403rd out of 454 stocks

See Top Rated MarketRank™ Stocks Here

PRQR stock logo

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Price History

PRQR Stock News Headlines

September 19, 2023 | americanbankingnews.com
ProQR Therapeutics (NASDAQ:PRQR) PT Lowered to $1.80
September 17, 2023 | americanbankingnews.com
ProQR Therapeutics (NASDAQ:PRQR) Lowered to Hold at StockNews.com
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 7, 2023 | finance.yahoo.com
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
August 8, 2023 | finance.yahoo.com
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions
August 4, 2023 | msn.com
Chardan Capital Reiterates ProQR Therapeutics N.V (PRQR) Neutral Recommendation
August 4, 2023 | markets.businessinsider.com
4 Analysts Have This to Say About ProQR Therapeutics
August 3, 2023 | uk.finance.yahoo.com
ProQR Announces Second Quarter 2023 Operating and Financial Results
September 26, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
August 2, 2023 | technews.tmcnet.com
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets
August 1, 2023 | finance.yahoo.com
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
July 18, 2023 | finance.yahoo.com
PRQR Oct 2023 7.500 call
June 28, 2023 | stocknews.com
2 Biotech Stocks to Buy, 1 to Sell Now
June 28, 2023 | finance.yahoo.com
ProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last year
May 23, 2023 | markets.businessinsider.com
Chardan Capital Remains a Hold on ProQR (PRQR)
May 18, 2023 | finance.yahoo.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability
May 17, 2023 | msn.com
HC Wainwright & Co. Reiterates ProQR Therapeutics N.V (PRQR) Buy Recommendation
May 17, 2023 | msn.com
JMP Securities Reiterates ProQR Therapeutics N.V (PRQR) Market Outperform Recommendation
May 17, 2023 | msn.com
Analyst Ratings for ProQR Therapeutics
May 17, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)
May 16, 2023 | msn.com
Recap: ProQR Therapeutics Q1 Earnings
May 16, 2023 | finance.yahoo.com
ProQR Announces First Quarter 2023 Operating and Financial Results
May 9, 2023 | finance.yahoo.com
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
April 20, 2023 | finance.yahoo.com
ProQR Announces Upcoming Investor Conferences in April and May
April 18, 2023 | finance.yahoo.com
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
March 31, 2023 | benzinga.com
ProQR Therapeutics Stock (NASDAQ:PRQR), Earnings Estimates, EPS, and Revenue
March 30, 2023 | markets.businessinsider.com
Positive Report for ProQR (PRQR) from JMP Securities
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings
8/03/2023
Today
9/26/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
CUSIP
N/A
CIK
1612940
Web
www.proqr.com
Phone
(188) 166-7000
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.88
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.80
Forecasted Upside/Downside
+167.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,600,000.00
Net Margins
-1,427.27%
Pretax Margin
-1,433.16%
Return on Equity
-86.23%
Return on Assets
-34.38%

Debt

Debt-to-Equity Ratio
0.07
Current Ratio
5.71
Quick Ratio
5.71

Sales & Book Value

Annual Sales
$4.25 million
Price / Sales
27.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.85 per share
Price / Book
1.71

Miscellaneous

Outstanding Shares
80,820,000
Free Float
74,028,000
Market Cap
$117.19 million
Optionable
Optionable
Beta
-0.02
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Domenico Valerio Ph.D. (Age 67)
    Founder & Independent Chairman of Supervisory Board
    Comp: $79.35k
  • Mr. Daniel Anton de Boer (Age 40)
    Founder, CEO & Member of Management Board
    Comp: $1.41M
  • Mr. Rene K. Beukema (Age 59)
    Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board
    Comp: $315.27k
  • Dr. Gerard Platenburg (Age 59)
    Co-Founder & Chief Scientific Officer
  • Mr. Jurriaan Dekkers (Age 47)
    Chief Financial Officer
  • Ms. Sheila Sponselee (Age 39)
    VP & Head of People and Operations
  • Ms. Sarah Cue Kiely
    VP of Investor Relations & Corp. Communications
  • Ms. Sandra van der Kolk
    Jr. Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.

What is ProQR Therapeutics' stock price forecast for 2023?

6 analysts have issued 12-month target prices for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $1.80 to $5.00. On average, they expect the company's stock price to reach $3.88 in the next twelve months. This suggests a possible upside of 167.8% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2023?

ProQR Therapeutics' stock was trading at $3.70 at the start of the year. Since then, PRQR shares have decreased by 60.8% and is now trading at $1.45.
View the best growth stocks for 2023 here.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our PRQR earnings forecast.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) announced its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. The biopharmaceutical company earned $1.31 million during the quarter, compared to analysts' expectations of $2.77 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 86.23% and a negative net margin of 1,427.27%.

What ETF holds ProQR Therapeutics' stock ?

Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Marshall Wace LLP (0.38%), Monaco Asset Management SAM (0.29%), Renaissance Technologies LLC (0.25%), JPMorgan Chase & Co. (0.22%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $1.45.

How much money does ProQR Therapeutics make?

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $117.19 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

The company employs 130 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -